interesting data on scientific progress, and I thank all those who have provided details (.... I, with my "macaronic" English, would never have been able to understand ..)

Overall it doesn't look bad (... apart from marketing by the end of the year, did I get it wrong?)
Instead, in my opinion, it is no good that on January 8 Joe announced the following:
"..... I will update everyone on our progress and timing on the NuGenerex Immuno-Oncology Nasdaq listing now that our third-party valuation analysis has been completed with a value estimated at over $ 500 million. This third-party valuation report is the last piece of information required to enable us to set the price per share to meet the standards for the Nasdaq. I will also provide a complete corporate update including discussions of our subsidiaries ".

Why persevere in continuing to announce topics that will be covered ... and that are then not mentioned? a month ago it was not known that we would be in "a quiet time?"
In this way, false expectations are created, and the result is what we saw yesterday, which is to lose 1/4 of its value ...
Too bad, the last cc were a disaster on the quotation, ... like a masochist who enjoys self-flagellation.